Skip to main content

Table 1 Baseline a characteristics

From: Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs

Characteristics Oral nonbiologic DMARD patients MTX patients Biologic DMARD patients
  N = 1,698 N = 1,217 N = 3,263
Demographics    
Age, mean (SD) 49.8 (12.5) 49.8 (12.3) 49.4 (11.6)
Female, number (%) 927 (54.6) 657 (54.0) 1,736 (53.2)
Combination of treatment with another nonbiologic DMARD and/or oral corticosteriod at the index date 168 (9.9) 138 (11.3) 1,512 (46.3)
During the 6-month pre-index period, including the index date    
Specialist encounter, number (%)    
Rheumatologist or Dermatologist 1,175 (69.2) 841 (12.3) 2,347 (71.9)
Rheumatologist 1,055 (62.1) 755 (62.0) 2,008 (61.5)
Dermatologist 384 (22.6) 271 (22.3) 896 (27.5)
During the 6-month pre-index period    
Comorbiditiesb,c, number (%)    
Hypertension 364 (21.4) 260 (21.4) 670 (20.5)
Diabetes 175 (10.3) 129 (10.6) 376 (11.5)
Hypothyroidism 114 (6.7) 81 (6.7) 200 (6.1)
Chronic pulmonary disease 111 (6.5) 72 (5.9) 176 (5.4)
Deficiency anemia 77 (4.5) 62 (5.1) 164 (5.0)
Psoriasis 545 (32.1) 420 (34.5) 1,194 (36.6)
Charlson comorbidity index, mean (SD) 0.47 (0.87) 0.44 (0.84) 0.52 (0.88)
Prior use of NSAID, oral corticosteriod, and nonbiologic DMARDs, number (%)    
NSAIDs 991 (58.4) 701 (57.6) 1,665 (51.0)
Oral corticosteriods 550 (32.4) 396 (32.5) 1,036 (31.7)
Nonbiologic DMARDs 0 (0.0) 0 (0.0) 1,938 (59.4)
  1. aThe baseline period consisted of the 6-month period prior to the index date. bElixhauser A, Steiner C, Kruzikas D. Comorbidity Software. January 2004. HCUP Methods Series Report #2004-1. Online, February 6, 2004. US Agency for Healthcare Research and Quality: pp 12-15 [16]. c Only mental and physical comorbidities where at least one of the reported cohorts had a prevalence of ≥5% were reported in the table. DMARD, disease-modifying antirheumatic drugs; MTX, methotrexate; number, number of patients; NSAID, nonsteroidal anti-inflammatory drug.